A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Way Cross-over Study to Evaluate the Effect of AF-219 on Methacholine Hyper-reactivity in Subjects With Asthma
Phase of Trial: Phase II
Latest Information Update: 21 Apr 2017
Price : $35 *
At a glance
- Drugs Gefapixant (Primary)
- Indications Asthma
- Focus Pharmacodynamics
- Sponsors Afferent Pharmaceuticals
- 12 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Mar 2014 Status changed from not yet recruiting to recruiting, as per European Clinical Trials Database record.
- 27 Nov 2013 New source identified and integrated: ClinicalTrials.gov record.